Intelligence Β· Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe β grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring β€24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months β use filters for patent-cliff planning.
-
US 6984379
Gene therapy by administration of genetically engineered CD34+ cells obtained from cord blood
expired -
US 6984381
Vaccine for the prevention of bacterial infection of the bovine mammary gland
expired -
US 6982168
Immortal human prostate epithelial cell lines and clones and their applications in the research and therapy of prostate cancer
expired -
US 6979724
Calcium channel proteins
expired -
US 6977241
SH2 domain binding inhibitors
expired -
US 6977245
Oligodeoxynucleotide and its use to induce an immune response
expired -
US 6977272
Method for antagonizing inhibition effects of alcohol on cell adhesion
expired -
US 6974698
Methods for delivering biologically active molecules into cells
expired -
US 6969602
Production of an immunovariant strain of Eimeria maxima contributes to strain cross-protection with other Eimeria maximas
expired -
US 6969609
Recombinant vector expressing multiple costimulatory molecules and uses thereof
expired -
US 6965017
Melanoma antigens and their use in diagnostic and therapeutic methods
expired -
US 6965022
Methods to identify swine genetically resistant to F18 E. coli associated diseases
expired -
US 6963769
Method for enhancing contrast produced by MRI
expired -
US 6962987
Binding domains from Plasmodium vivax and Plasmodium falciparum erythrocyte binding proteins
expired -
US 6958319
Formulation of boronic acid compounds
expired -
US 6955895
Thymic stromal lymphopoietin receptor molecules and uses thereof
expired -
US 6951915
Redox-stable, non-phosphorylated cyclic peptide inhibitors of SH2 domain binding to target protein, conjugates thereof, compositions and methods of synthesis and use
expired -
US 6951917
MHC-class II restricted melanoma antigens and their use in therapeutic methods
expired -
US 6951846
Artemisinins with improved stability and bioavailability for therapeutic drug development and application
expired -
US 6949530
Nitric oxide-releasing amidine diazeniumdiolates, compositions and uses thereof and method of making same
expired -
US 6949624
Cloning of the human nuclear receptor co-repressor gene
expired -
US 6946133
Prostate specific antigen oligo-epitope peptide
expired -
US 6946246
Production of functional proteins: balance of shear stress and gravity
expired -
US 6943191
Disubstituted lavendustin A analogs and pharmaceutical composition comprising the analogs
expired -
US 6939546
Model for testing immunogenicity of peptides
expired -
US 6939864
Animal feed compositions and methods of using the same
expired -
US 6939547
Specific binding agents for KSHV vIL-6 that neutralize a biological activity
expired -
US 6936639
Nitroxyl progenitors in the treatment of heart failure
expired -
US 6933277
Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides
expired -
US 6930176
Major neutralization site of hepatitis E virus and use of this neutralization site in methods of vaccination and in methods of screening for neutralizing antibodies to hepatitis E virus
expired -
US 6924367
Method of modulating tissue growth using Frzb Protein
expired -
US 6924362
Monoclonal antibodies specific for the E2 glycoprotein of hepatitic C virus and their use in the diagnosis, treatment, and prevention of hepatitis C
expired -
US 6923971
Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
expired -
US 6919442
Nucleic acids comprising a post-transcriptional regulatory element (PRE) and their uses
expired -
US 6916905
Dmt-Tic di-and tri-peptidic derivatives and related compositions and methods of use
expired -
US 6916843
Anti-inflammatory actions of cytochrome P450 expoxygenase-derived eicosanoids
expired -
US 6911478
Nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same
expired -
US 6911433
O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates
expired -
US 6911527
HIV related peptides
expired -
US 6906169
Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of Ξ²-amyloid peptide
expired -
US 6905680
Methods of treating HIV infected subjects
expired -
US 6905681
Methods for selectively stimulating proliferation of T cells
expired -
US 6902743
Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
expired -
US 6903184
Multiple antigenic peptides immunogenic against Streptococcus pneumonia
expired -
US 6900024
T cell receptor ligands and methods of using same
expired -
US 6897227
Prodrugs of proton pump inhibitors
expired -
US 6897018
DLC-1 gene deleted in cancers
expired -
US 6893869
Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
expired
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory